

ICPM 2018 (International Conference in Pharmaceutical Medicine)

Workshop 8

Best Practices in Pharmaceutical Medicine*

Chair and written by Kotone Matsuyama¹⁾, Anna Jurczynska²⁾

Topics: Brazil

Korea

Italy

Japan

Philippines

Singapore

Presenters: Wellington Briques³⁾

SungJa Cho⁴⁾

Domenico Criscuolo⁵⁾

Kazuya Iwamoto⁶⁾

Milagros Liwag Tan-Pineda⁷⁾

Ajay Tiku⁸⁾

1) Nippon Medical School, Japan

2) AMIFE, Spain

3) SBMF, Brazil

4) Janssen, Korea

5) SIMeF, Italy

6) Covance, Japan

7) PCPM, Philippines

8) GSK, Singapore

Learning objectives

By participating in our session, you'll learn about the focuses and best practices given to Pharmaceutical Medicine in different countries and continents (Asia, Europe, South America), presented by representatives on these three regions.

Learning Outcomes:

- Discuss the role of local associations in promoting pharmaceutical medicine in their countries.
- Learn from the experience of other associations on how to foster education in pharmaceutical medicine.

* This is a summary of the outcome of Workshop 6 provided on September 28, 2018, in the 19th International Conference in Pharmaceutical Medicine (ICPM) in Tokyo, Japan, organized by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP). Japanese version is included in Clinical Evaluation. 2019; 47(2).

Color version: http://cont.o.oo7.jp/47_2/47_2contents_e.html

- Consider the role of local associations in relationships with regulatory agencies.
- Extrapolate experience from other countries on the world-wide level.

Outcomes

Workshop 8 was dedicated to best practices and educational activities developed by several National Member Associations (NMAs) of IFAPP.

In order to learn more about different approaches to best practices in Pharmaceutical Medicine (PM) in various countries from Asia, Europe and South America, six (6) speakers were invited to expose their experience: Brazil, Italy, Japan, Korea, Philippines and Singapore.

Clearly, there were some common points and issues in all of these countries, representing three major continents: educational activities as the driving force for integrating physicians, healthcare professionals and scientists in medicine development; relationship with Regulatory Agency to influence regulations and local and international laws on drug development.

Brazil was represented by the local association in PM, SBMF (Brazilian Society of Pharmaceutical Medicine), with 46 years of experience on the market. They established strategic relationship with ANVISA (Regulatory Agency), Interfarma, Health Ministry, Sindusfarma and other in order to run educational activities aimed at guaranteed a fluent contact with major stakeholders.

A representative from the Italian association, SIMeF (abbreviation for The Italian Association of Pharmaceutical Medicine), focused on excellent relationship with AIFA and NIH (Regulatory Agencies) and their active participation on Basic Course and Master Courses in PM.

The Japanese association of pharmaceutical medicine, JAPhMed, built their activities on 5 Committees: Education, Public Relations, Medical Affairs, Medical Safety and Kansai. Their goal is to enhance awareness of PM through courses, seminars and symposia, with participation of experts from Regulatory Agency

The Korean Society of Pharmaceutical Medicine, KSPM, gave an overview of their Master in PM and Regulatory Sciences run jointly with the Colleges of Medicine and Pharmacy, as well as an Advanced Course on PM and continuous professional development. PM was established as medical specialty in 1995.

Philippines representative from PCPM (Philippine College of Pharmaceutical Medicine) underlined the importance of continuing education and presented the Diploma Course in PM and Management in partnership with an University of Manila with participation of experts from Regulatory Agency, Academia and Medical Societies. Positive feedback was received from the students attending these courses.

The Association of Pharmaceutical Medicine Singapore, APMS, has developed several courses and symposia in Medical Affairs and organized quarterly networking events with participation of pharmaceutical industry representatives and experts from Regulatory Institutions.

Conclusion

Finally, the learning outcomes of this interesting session was the role of local associations in promoting pharmaceutical medicine in their countries; exchange of experience of other associations on how to foster education in pharmaceutical medicine and strong focus on relationships with regulatory agencies.

* * *